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Abstract: The therapeutic landscape of non–small-cell lung cancer 
(NSCLC) has dramatically changed in the last few years with the 
introduction of molecularly targeted agents, leading to unprecedented 
results in lung tumors with a paradigmatic shift from a “one size fits 
all” approach to an histologic and molecular-based approach. The 
discovery of epidermal growth factor receptor (EGFR) mutations 
in NSCLC in 2004 and the marked response to the EGFR tyrosine 
kinase inhibitor gefitinib, in a small subset of patients harboring these 
genetic abnormalities, stimulated the study of other kinase mutants 
involvement in NSCLC. The incredible story of ALK rearranged 
tumors, with the rapid Food and Drug Administration approval of 
Crizotinib after only 4 years from the discovery of EML4-ALK 
translocation in NSCLC, has profoundly influenced the concept of 
drug development in NSCLC, paving the way to a novel series of 
molecularly selected studies with specific inhibitors. The identifica-
tion of these oncogenic drivers has dramatically changed the genetic 
landscape of NSCLC moving away from the old concept of a large 
indistinct histological entity to a combination of rare clinically rel-
evant molecular subsets. Recently, a renewed interest has been 
emerging on the human epidermal growth factor-2 (HER2) pathway. 
Genetic aberrations of this signaling pathway have been reported 
over time to be associated in NSCLC with different sensitivity to 
the EGFR tyrosine kinase inhibitors, to have a possible prognostic 
role and more recently HER2 amplification has been emerged as a 
possible mechanism in EGFR-mutated tumors of acquired resistance 
to the EGFR tyrosine kinase inhibitors. In addition, dysregulation of 
the HER2 pathway, in particular HER2 mutations (mostly, in-frame 
exon 20 insertions), may represent a possible novel therapeutic target 
in NSCLC, paving the way for a new generation of targeted agents 
in NSCLC. Since anecdotal case reports of clinical activity of anti-
HER2 agents in NSCLC patients with HER2 mutations, several 
targeted agents have been evaluated in HER2-mutated patients, gen-
erating a growing interest upon this oncogenic driver, leading to the 
design of molecularly selected trials with anti-HER2 compounds and 
the rediscover of hastily thrown out drugs, such as neratinib. The aim 
of this article is to provide an overview of the role of HER2 dysregu-
lation in NSCLCs, trying to throw a light not only on the strengths 
but also the weaknesses of the studies conducted so far. It is a long 
way to the clinical implementation of these biomarkers and probably 
the increasing use of next generation sequencing techniques, the cre-
ation of large multi-institutional molecular testing platforms and the 
design of rationally based trials can get closer personalized medicine 
in NSCLC.
(J Thorac Oncol. 2014;9: 1750–1762)
The therapeutic landscape of non–small-cell lung cancer (NSCLC) has dramatically changed in the last few years 
with the introduction of molecularly targeted agents, lead-
ing to unprecedented results in lung tumors with a paradig-
matic shift from a “one size fits all” approach to an histologic 
and molecular-based approach. Despite initial controversial 
results in unselected patients with only one study, the BR.21 
trial, demonstrating an overall survival advantage over pla-
cebo,1 the use of epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors (TKIs) has emerged as the optimal 
treatment option in molecularly selected patients based on the 
presence of activating mutations in the tyrosine kinase domain 
of EGFR.2,3 The discovery of EGFR mutations in NSCLC in 
2004 and the marked response to the EGFR TKI gefitinib, in 
a small subset of patients harboring these genetic abnormali-
ties,4,5 stimulated the study of other kinase mutants involve-
ment in NSCLC.
The incredible story of ALK rearranged tumors, with the 
rapid Food and Drug Administration approval of Crizotinib 
after only 4 years from the discovery of EML4-ALK trans-
location in NSCLC,6 has profoundly influenced the concept 
of drug development in NSCLC, paving the way to a novel 
series of molecularly selected studies with specific inhibitors. 
Despite the relative low frequency of these genetic abnormali-
ties, an oncogenic driver can be detected, for instance, in 14% of 
lung adenocarcinomas, the most extensively studied histotype 
(64% if we include also EGFR mutations, KRAS mutations, 
and ALK rearranged tumors) and a significant proportion of 
these patients may be treated with genotype-directed therapy.7 
The identification of these oncogenic drivers has dramatically 
changed the genetic landscape of NSCLC moving away from 
DOI: 10.1097/JTO.0000000000000379
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/14/0912-1750
NSCLC and HER2
Between Lights and Shadows
Giuseppina Rosaria Rita Ricciardi, MD, Alessandro Russo, MD, Tindara Franchina, MD,  
Giuseppa Ferraro, MD, Mariangela Zanghì, MD, Antonio Picone, MD, Antonino Scimone, MD,  
and Vincenzo Adamo, MD
Medical Oncology Unit AOOR Papardo-Piemonte, Department of Human 
Pathology, University of Messina, Messina, Italy.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Vincenzo Adamo, MD, Medical Oncology Unit 
AOOR Papardo-Piemonte, Department of Human Pathology, University 
of Messina, Messina, Italy. E-mail: vadamo@unime.it
STATE OF THE ART: CONCISE REVIEw
1751Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 12, December 2014 NSCLC and HER2
the old concept of a large indistinct histologic entity to a com-
bination of rare clinically relevant molecular subsets.
Recently, a renewed interest has been emerging on the 
human epidermal growth factor-2 (HER2) pathway. Genetic 
aberrations of this signaling pathway have been reported 
over time to be associated in NSCLC with different sensitiv-
ity to the EGFR TKIs, to have a possible prognostic role and 
more recently have been emerged as a possible mechanism 
in EGFR-mutated tumors of acquired resistance to the EGFR 
TKIs. In addition, dysregulation of the HER2 pathway, in par-
ticular HER2 mutations, may represent a possible novel thera-
peutic target in NSCLC, paving the way for a new generation 
of targeted agents in NSCLC. Since anecdotal case reports of 
clinical activity of anti-HER2 agents in NSCLC patients with 
HER2 mutations,8 several targeted agents have been evaluated 
in HER2-mutated patients, generating a growing interest upon 
this oncogenic driver, leading to the design of molecularly 
selected trials with anti-HER2 compounds and the rediscover 
of hastily thrown out drugs, such as neratinib.
The aim of this article is to provide an overview of the 
role of HER2 dysregulation in NSCLCs. Our review distances 
itself from other previous reviews that have evaluated the role 
of HER2 pathway in NSCLC because it is a critical analysis 
of the available evidences of the clinical implications of HER2 
abnormalities, trying to throw a light not only on the strengths 
but also the weaknesses of the studies conducted so far. It is a 
long way to the clinical implementation of these biomarkers 
and probably the increasing use of next generation sequencing 
techniques, the creation of large multi-institutional molecular 
testing platforms and the design of rationally based trials can 
get closer personalized medicine in NSCLC.
HER2 PATHWAY AT A GLANCE
The ERBB receptors family is the prototype of tyrosine 
kinase receptors and is composed of four members: EGFR 
(also known as HER1 or ERBB1), ERBB2 (HER2), ERBB3 
(HER3), and ERBB4 (HER4). Each receptor is composed 
of an extracellular domain for ligand binding, an α-helical 
transmembrane segment and an intracellular tyrosine kinase 
domain. ERBB receptors are activated by binding to growth 
factors of the EGF family. Ligand binding to the extracellular 
domain initiates a conformational rearrangement that allows 
dimerization. Receptor dimerization is essential for ERBB 
function and can occur between two different ERBB recep-
tors (heterodimerization) or between two molecules of the 
same receptor (homodimerization). Ligand binding promotes 
receptor dimerization and self-phosphorylation of specific 
tyrosine residues within the cytoplasmic tail, that serves as 
docking sites for various adaptor proteins containing SH2 and 
PTB domains, allowing activation of intracellular signaling 
cascades, including MAPK and PI3K/Akt pathways.9–14
Although all four ERBB receptors possess the same 
essential domains, the functional activity of each domain var-
ies. Indeed, ERBB3 can bind to several ligands but lacks intrin-
sic tyrosine kinase activity and can only heterodimerize with 
other ERBB receptors. Instead, ERBB2 has an active tyrosine 
kinase domain but lacks a specific ligand and is the favored het-
erodimerization partner of the other ERBB receptors. It exists 
in the extended “active” conformation state, allowing it to be 
constantly primed for interactions with ligand-bound recep-
tors of the family. ERBB2-containing heterodimers mediate 
potent mitogenic signals owing to its peculiar properties: it 
binds to a much larger subset of phosphotyrosine-binding pro-
teins than the other receptors of the family; its heterodimers 
are characterized by a higher affinity and broader specificity 
for various ligands than the other heterodimeric complexes, 
owing to slow rates of growth-factor dissociation; and finally 
ERBB2-containing heterodimers undergo slow endocytosis, 
and they more frequently recycle back to the cell surface.10,13
Although neither ERBB2 nor ERBB3 alone can be 
activated by ligand, the ERBB2/ERBB3 heterodimer is con-
sidered the most potent ERBB pair with respect to strength 
of interaction, ligand-induced tyrosine phosphorylation, and 
downstream signaling.13,14
The discovery of HER2 dates back at the mid-1980s 
when the laboratory of Robert weinberg first isolated DNA 
from carcinogen-induced tumors, introduced it into normal 
fibroblasts and screened for putative oncogenes, identifying a 
nucleotide sequence of a cDNA clone (that they termed Neu), 
predicting a transmembrane protein similar to the EGFR. 
Subsequent efforts of three different laboratories yielded to 
the human ortholog of Neu, named ERBB2 or HER2.15 After 
its discovery, dysregulation of HER2, along with EGFR, has 
been implicated in the pathogenesis of many human tumor 
types and includes gene amplification (that leads to recep-
tor overexpression), activating kinase domain mutations, 
and coexpression of ERBB ligands and receptors. All these 
abnormalities, ultimately, lead to constitutive activation of the 
receptor and, in turn, upregulation of several signaling path-
ways that drive cancer development.11
In the subsequent sections, we will focus on the altera-
tions of the HER2 pathway in NSCLC, trying to point out 
a comprehensive overview of the prognostic and predic-
tive effect of its deregulations and their potential clinical 
implications.
HER2 OVEREXPRESSION IN NSCLC
The HER2 overexpression is found in patients with dif-
ferent solid tumors, including NSCLC. Although it is a well-
established prognostic and predictive factor in HER2-positive 
patients with breast cancer, its role in lung malignancies is far 
less defined.
HER2 overexpression has been reported with differ-
ent frequency values in NSCLC patients with extremely wide 
ranges. Frequency disparities are likely due to differences in 
the methodologies applied and patient populations studied. 
Immunohistochemistry (IHC) was the most frequently used 
method to detect HER2 overexpression. However, immuno-
histochemical results can vary according to the primary anti-
body used, the dilution of the antibody, the different tissue 
samples used (i.e., paraffin-embedded versus frozen samples), 
the cutoff used for establishing HER2 positivity and whether 
membrane or cytoplasmic reactivity are assessed. In addition, 
different patient populations were evaluated, creating possible 
interpretation bias because low number of patients in some 
studies might explain the inconsistency of the prognostic 
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impact of HER2 overexpression. Moreover, the differences in 
the histology of tumors and the stage might have had an impact 
in these discrepancies. Restricting the frequency analysis to 
the studies utilizing the IHC HercepTest (Table 1), the overall 
frequency of HER2 overexpression, in terms of IHC 2+/3+, 
ranges from 4.3%16,17 to 34.9%,18 reaching higher frequencies 
in selected patients populations, such as bronchioloalveolar 
carcinoma patients (43%).19
A significant overlap between IHC 3+ staining and HER2 
amplification, documented by FISH analysis, was reported in 
NSCLC,16,18,20–22 albeit cases IHC negative or with low staining 
have been reported to be FISH positive.20,21,23 There are several 
potential reasons for these discrepant results, such as quality 
of fixation and tissue processing, as well as disturbances in 
the transcriptional or post-transcriptional controlling mecha-
nisms, and in the case of 2+ overexpressing tumors, perhaps 
mechanisms other than gene amplification (autocrine loop, 
mutation) may be the cause of the immunopositive results.21,24
IHC positivity has been variously associated with 
different clinic-pathological features, including adeno-
carcinoma histology (including the bronchioloalveolar 
 subtype)21,22,25–30 and large-cell carcinoma,21,22 advanced and 
metastatic disease,16,31,32 nodal involvement,33 poor tumor dif-
ferentiation,22,30,34 lower performance status, and weight loss at 
baseline.35 However, in these studies, as well as in others, not 
all these features were confirmed to be associated with HER2 
overexpression and in some instances were rejected.27,30,31,37–40
In addition to IHC assays, other authors have attempted 
to evaluate HER2 expression with other methodologies, such 
as real-time polymerase chain reaction assay. Brabender 
et al.,41 using a cutoff value of 1.8 ratio between lung tumors 
and normal tissues, reported that high HER2 mRNA levels 
were associated with an unfavorable prognosis and that the 
impact of HER2/EGFR co-expression on survival was addi-
tive (p = 0.176). These results are consistent with another 
study that reported synchronous overexpression of EGFR 
and HER2 being associated with shorter disease-free sur-
vival (p = 0.006) and overall survival (p = 0.027) in stage I 
NSCLC patients.29 The role of EGFR and HER2 co-existence 
in NSCLC has also been evaluated as a predictive biomarker 
for gefitinib activity,42,43 suggesting that dual targeting of these 
receptors may provide an advantage in selected subgroups of 
patients.
In addition, Vallböhmer et al.,44 using a real-time poly-
merase chain reaction assay, found that gene expression levels 
of HER2/neu in the primary tumors of 90 patients with cur-
able resected NSCLC was correlated with survival, but only 
in women. Indeed, women with a low expression of HER2/
neu had a significantly longer survival time compared with 
women who had high HER2/neu expression levels, whereas 
no significant difference for the survival time was found com-
paring with men. However, the molecular mechanisms of this 
apparent sex specificity remain unknown.
The prognostic role of HER2 overexpression has been 
extensively evaluated and was the subject of three distinct 
meta-analyses,27,45,46 reporting a poor prognostic effect. In 
particular, the most recent one,46 analyzing 40 studies (6135 
patients), showed that HER2 overexpression was significantly 
associated with a poor prognosis in NSCLC (hazard ratio 
1.48), even in early-stage disease. when the authors restricted 
the analysis to squamous cell carcinomas, they did not found 
any prognostic effect. However, these results should be inter-
preted with cautions because inherited biases are present in 
this type of studies, such as publication and selection biases. 
In addition, the meta-analysis of Liu et al.46 was literature 
based and was not founded on individual patient data, pre-
venting from performing multivariate analyses to exclude the 
possible effect of other confounding factors, such as stage, 
age, sex, etc.
A possible explanation for the shorter overall survival 
(OS) observed among HER2-positive NSCLCs may be the 
intrinsic chemoresistance of these tumors.47
Tsai et al.48 first reported intrinsic chemoresistance 
of NSCLC cell lines with HER2 gene expression, assessed 
through Northern Blotting assay, to six commonly used che-
motherapy agents, including cisplatin. Moreover, they reported 
that transfecting of the HER-2/neu gene into an NSCLC cell 
line expressing very low intrinsic levels of p185neu enhances 
chemoresistance in the transfectant clones greatly49 and that 
NSCLC cell lines from untreated patients exhibited relatively 
chemoresistance when expressing high levels of p185neu.50
Accordingly with in vitro studies, Junker et al.40 evalu-
ating HER2 status with both IHC and FISH in pretreatment 
samples of IIIA N2 and IIIB NSCLC patients before and in 
the same patients after surgery, reported that HER2 express-
ing tumors showed a trend toward a minor therapy-induced 
tumor regression, suggesting that HER2 tumors are relatively 
resistant to chemotherapy and radiation. In contrast, others 
reported that neither HER2-FISH51 nor IHC status51,52 were 
associated with objective response to the chemoradiotherapy 
in locally advanced NSCLCs. These results are consistent 
with another study,53 evaluating the predictive value of EGFR 
and HER2 gene copy number to first-line chemotherapy, that 
did not find any difference in terms of response to chemother-
apy between FISH-positive and FISH-negative patients with 
advanced NSCLC (p = 0.5); however, HER2 FISH-positive 
patients treated with an EGFR TKI, as second or third line, 
had higher response rate (RR), time to progression (TTP), and 
OS, whereas in HER2 FISH-negative patients chemotherapy 
produced higher RR and longer TTP.53
Because HER2 is the preferred EGFR partner and pre-
clinical data suggest that HER2 overexpressing cells are sensi-
tive to gefitinib,54–59 some authors have evaluated the impact of 
HER2 dysregulation on EGFR TKIs sensitivity. Before EGFR 
mutations discovery, Cappuzzo et al.18 evaluated the impact of 
HER2 overexpression by IHC in 63 unselected patients with 
NSCLC treated with gefitinib. Among the 43 patients evalu-
able for EGFR and HER2 status, they reported a frequency 
of 55.8% and 34.8% (18.6% IHC 3+), respectively, positive 
cases, but no effect in terms of TTP or OS neither for HER2 
positivity nor for concurrent HER2/EGFR overexpression. 
In a similar patients population, Noberasco et al.17 reported, 
among 23 patients evaluable for EGFR and HER2 overexpres-
sion and treated with gefitinib, 11 partial response (PR)/stable 
disease (SD) and 12 progressive disease (PD). Interestingly, 
the only patient HER2 IHC 3+ had a PR, whereas the three 
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TAbLE 1.  Selected Studies Reporting HER2 Overexpression in NSCLC by IHC (HercepTest)
References Sample Size (n) Hystotype
HER2 Overexpression  
(IHC) (2+/3+)
HER2 Amplification 
by  
FISH Comments
Cappuzzo  
et al.18
43 NSCLC 34.8% (18.6% IHC 3+) Three of 15 pts IHC 
2+/3+
No difference in terms of TTP and OS for pts treated with 
gefitinib in HER2 and HER2/EGFR overexpressing pts
Capuzzo  
et al.42
102 NSCLC 7% (score ≥200) 22.8% (high 
polysomy and gene 
amplification)
The outcome of double-positive pts was significantly better 
than that of the HER2 FISH-negative/EGFR-positive or 
HER2-negative and/or EGFR-negative patients
Cox et al.16 344 NSCLCs 4.3% (2.0% IHC 3+) Four cases (all IHC 3+) IHC positivity associated with advanced stage
Erman  
et al.19
15 (14 evaluated) BAC 43% (four of six IHC 3+) — —
Gatzemeier  
et al.62
619 NSCLC  
(IIIB/IV)
~17% NR The addition of trastuzumab to CG did not provide 
any benefit in HER2 IHC 2+ pts; however, pts with 
very strong overexpression (IHC 3+) and/or HER2 
amplification (<2% of pts) exhibited higher RR and 
PFS.
Heinmöller  
et al.20
563 NSCLCs 20.2% (1.7% IHC 3+) 1.8% (4% in ADCs) —
Hirsch  
et al.21
238 NSCLCs 16% (4% IHC 3%); 35% 
among ADCs and 20% 
among LCC
4% (8% in ADCs only) 
(only 51 pts  
evaluated)
Tendency to shorter survival for IHC 3+ (not significant 
due to small size)
Junker  
et al.40
−105  
(pretreatment);
−44 (resection 
specimens after 
neoadjuvant  
therapy)
NSCLC
(IIIA N2, IIIB)
−7.6% (No IHC 3+ cases); 
−13.7%  
(IHC 3+ in 2.3%)
−4.8%; −-4.6%. No 
tumors with high-
grade amplification  
in both pretreatment 
and resected tumors
HER2 overexpression/amplification was slightly higher 
in ADCs (difference not statistically significant); no 
correlation with stage. Trend toward a minor response to 
neoadjuvant therapy (p = 0.069)
Krug  
et al.35
179 NSCLC  
(IIIB/IV)
16% 16% (among 47 pts 
evaluable)
Pts with HER-2 overexpression were found to be more 
likely to have a lower PS and weight loss at baseline
Kuyama  
et al.51
68 NSCLCs (locally 
advanced)
34% (10% IHC 3+) NR HER2-FISH status was an independent prognostic factor 
for poor OS and DFS, whereas IHC status did not affect 
neither OS nor PFS
Langer  
et al.61
129 NSCLC  
(IIIB/IV)
31, 6%a (9.3% IHC 3+) — Patients with IHC 3+ expression, treated with trastuzumab 
+ CP, experienced a survival exceeding that of historical 
controls
Lara  
et al.64
69 NSCLC  
(IIIB/IV)
19% (5.8% IHC 3+) Two of 14 pts  
(ratio >2)
The vast majority of HER2 positive patents were ADCs
Noberasco  
et al.17
23 NSCLC 4.3% (IHC 3 +) — IHC 3+ in one patient achieving a PR with gefitinib, 
whereas three patients with IHC 1+ had PD
Onn  
et al.29
111 NSCLCs  
(Stage I)
17.1% (more common in  
ADCs than SqCCs:  
p = 0.035; and in T2 tumors 
than T1: p = 0.001)
— Synchronous overexpression of EGFR and HER2 was 
associated with shorter DFS (p = 0.006) and OS  
(p = 0.027)
Pelosi  
et al.23
345 NSCLCs  
(Stage I)
8.4% with the FDA- 
approved scoring system 
and 12.5% with the lung-
modified scoring system
7.4% —
Tan  
et al.22
140 NSCLCs  
(Stage I–IIIA)
19% (23% in ADCs and  
40% in LCCs)
5%  
(gene amplification); 
11% displayed 
polysomy
The relationship between the two major subtypes (ADC 
and SqCC) of NSCLC and HER-2/neu expression was 
statistically significant; HER-2/neu alternation was 
significantly associated with poorer tumor differentiation
Zinner  
et al.63
360 NSCLC  
(IIIB/IV)
13% (5% IHC 3+) — Comparing the IHC and serum ELISA results, the authors 
found a weak but statistically significant relationship 
between the positive and negative results when considering 
IHC 3+ and serum >15 ng/ml positive
aMany investigators prescreened their patients.
FDA, Food and Drug Administration; ADCs, adenocarcinomas; NSCLCs, non–small-cell lung cancer; IHC, immunohistochemistry; CG, cisplatin–gemcitabine; CP, carboplatin–
paclitaxel; pts, patients; PS, performance status; OS, overall survival; DFS, disease-free survival; PR, partial response; PD, progressive disease; BAC, bronchioloalveolar carcinoma; 
LCC, large-cell carcinoma, SqCC, squamous cell carcinoma; TTP, time to progression; EGFR, endothelial growth factor receptor; RR, response rate; PFS, progression-free survival; 
ELISA, enzyme-linked immunosorbent assay; NR, not reported.
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ones with low staining (IHC 1+) progressed on gefitinib, sug-
gesting that a strong positivity, albeit unusual in NSCLC, 
might help to predict response to gefitinib in unselected 
patients. The relative rarity of HER2 IHC 3+ cases and the 
discovery of EGFR mutations as major determinant of EGFR 
TKIs sensitivity have limited further studies in this setting.
The predictive role of HER2 overexpression has been 
more extensively studied for anti-HER2 agent trastuzumab in 
NSCLC patients. Given its well-defined role in the treatment 
of HER2-positive breast cancer and the preclinical evidence 
of activity in NSCLC cell lines expressing HER2 either alone 
or in combination with chemotherapeutic agents (with the 
greatest synergy with gemcitabine),60 trastuzumab has been 
studied in advanced NSCLC with HER2 activation (Table 2). 
The clinical definition of HER2 activation varied among these 
studies, depending on the eligible criteria: IHC (2+/3+), HER2 
amplification by FISH or high HER2 serum levels by enzyme-
linked immunosorbent assay (ELISA) (>15 ng/ml). Overall, 
these studies failed to demonstrate a significant advantage of 
adding trastuzumab to conventional first-line chemotherapy 
doublets,61–63 to taxanes35,64 or as single agent.65 Despite these 
disappointing results, restricting the analysis to the patients 
with strong IHC expression (3+) or with HER2 amplification, 
a suggestion of higher efficacy for the addiction of trastu-
zumab to platinum doublets has emerged,61,62 but the paucity 
of patients exhibiting these genetic characteristics in conjunc-
tion with the unclear survival benefit have made impractical 
further studies in this direction.
HER2 AMPLIFICATION
Gene amplification is a well-known mechanism of 
proto-oncogene activation and has been described in many 
human malignancies, including lung tumors.
However, HER2 amplification seems far less common in 
NSCLC compared with breast cancer and is more frequently 
a consequence of chromosome 17 polysomy rather than gene 
amplification.21 In advanced/metastatic gastric cancer, more 
frequently diffuse type, HER2 amplification/overexpression 
has been associated in the TOGA trial with improved outcome 
in patients treated with trastuzumab-based regimens, paving 
the way to use of anti-HER2 agents in this setting.66
Different methodologies have been described to assess 
HER2 genomic gain in NSCLC. There is a general consen-
sus that gene/chromosome ratio of greater than 2, determined 
by FISH, represents true gene amplification; however, other 
parameters have also been used;21 therefore, the detection 
 frequency varied widely among the different studies (Table 3).
In some studies, detection of HER2 amplification was 
associated with activating mutations of the EGFR,42,43,67,68 
albeit the exact mechanism of this association remains 
unknown. In contrast, Endo et al.69 did not show any associa-
tion between HER2 amplification and EGFR mutations and 
Pugh et al.70 showed that HER2 FISH positivity did not cor-
relate with EGFR mutations or amplifications, gender, ethnic-
ity, smoking status, adenocarcinoma histology, and gefitinib 
activity.
HER2 amplification has been associated with some 
clinic-pathologic features, such as female sex, never smoking 
status,42 adenocarcinoma histology,22,40 and prognosis. The 
prognostic impact of HER2 amplification detected by FISH in 
seven studies was evaluated in the meta-analysis of Liu et al.46 
and, on the contrary of that observed with IHC, no significant 
difference was seen.
Cappuzzo et al.42 evaluated the predictive role of HER2 
amplification in a cohort of NSCLC patients treated with 
gefitinib, reporting a better overall response rate (ORR), 
 disease control rate (DCR), and a longer TTP in the 23 HER2 
FISH-positive patients (22.8%). Among these, 19 had EGFR 
mutation analyses performed and eight had EGFR mutations, 
of whom all but one responded to gefitinib. Among the 11 
HER2 FISH-positive patients without EGFR mutation, three 
had SD and eight had progressive disease. Seven HER2 FISH-
positive and EGFR-positive (FISH, IHC, or mutation) patients 
responded to treatment. The outcome of double-positive 
patients was significantly better than that of the HER2 FISH-
negative/EGFR-positive or HER2-negative and/or EGFR-
negative patients. Of particular interest, among the seven 
patients with EGFR mutations but negative for FISH HER2, 
only one patient achieved objective response, and this group 
of patients had a poor outcome similar to that of the EGFR-
negative mutation groups, suggesting that high copy numbers 
of the HER2 gene increase sensitivity to gefitinib therapy. 
Conversely, in the absence of EGFR, HER2 alone is not able 
to drive gefitinib sensitivity. These results were confirmed by 
Daniele et al.43 who reported gefitinib sensitivity only when 
both HER2 and EGFR genes gain occurred.
In contrast, a study conducted in a Japanese cohort did 
not show any predictive role for HER2 amplification,71 and an 
Italian study that did not find any relevance for HER2 gene 
copy number gain, even when considering patients with con-
current EGFR and HER2 FISH positivity,68 albeit the small 
sample size in this study may have limited the value of HER2 
analysis (only 11 patients HER2 FISH positive and only eight 
patients EGFR and HER2 FISH positive). The picture emerg-
ing from these studies is complex because the results are 
sometimes conflicting. Differences in the study populations 
and sample size may explain, at least, in part these contrasting 
data. Notwithstanding these limitations, we can conclude that 
HER2 gene copy number may influence the response to gefi-
tinib, but much weaker than EGFR mutations, albeit stronger 
than the high EGFR copy number.67
HER2 amplification has been proposed as a mechanism 
of acquired resistance to the anti-EGFR monoclonal antibody 
cetuximab in colorectal cancer72,73 and activation of HER fam-
ily signaling has been associated with acquired resistance to 
ALK inhibitors,74 suggesting that activation of alternative 
receptor tyrosine kinase signaling (bypass tracks) is a common 
mechanism of escape to targeted agents. Recently, Takezawa 
et al.75 investigated the possible role of HER2 dysregulation 
in EGFR-mutant NSCLC cell lines, based on the preclini-
cal and clinical data of efficacy for the dual combination of 
afatinib (that inhibits EGFR, HER2, and HER4) and cetux-
imab in models of acquired resistance to EGFR TKIs. They 
first reported HER2 amplification as a novel mechanism of 
resistance to EGFR TKIs in NSCLC patients with a frequency 
of 12%, in the absence of T790M mutation, a well-known 
1755Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 12, December 2014 NSCLC and HER2
TA
b
LE
 2
. 
St
ud
ie
s 
w
ith
 T
ra
st
uz
um
ab
-C
on
ta
in
in
g 
Re
gi
m
en
s 
St
ud
ie
s 
in
 N
SC
LC
St
ud
y 
N
am
e
St
ud
y 
D
es
ig
n
E
lig
ib
ili
ty
 C
ri
te
ri
a
P
ts
 (
n
)
T
re
at
m
en
t A
rm
 (
s)
L
in
e 
(s
) 
of
 T
re
at
m
en
t
O
R
R
 (
C
R
/P
R
)
P
F
S 
(m
on
th
s)
O
S 
(m
on
th
s)
C
A
L
G
B
 3
98
10
65
P
ha
se
 I
I,
 
no
nr
an
do
m
iz
ed
H
E
R
2 
IH
C
 2
+
/3
+
24
w
ee
kl
y 
T
U
p 
to
 o
ne
 p
ri
or
 C
T
 
re
gi
m
en
5%
2.
6
5.
3
E
C
O
G
 2
59
86
1
P
ha
se
 I
I,
 
no
nr
an
do
m
iz
ed
H
E
R
2 
IH
C
 1
+
/2
+
/3
+
44
C
P
 +
 w
ee
kl
y 
T
Fi
rs
t l
in
e
24
.5
%
3.
3
10
.1
G
at
ze
m
ei
er
 e
t a
l.6
2
P
ha
se
 I
I,
 r
an
do
m
iz
ed
H
E
R
2 
IH
C
 2
+
/3
+
 
or
 H
E
R
2 
am
pl
ifi
ca
ti
on
 o
r 
se
ru
m
 H
E
R
2 
le
ve
ls
 
>
15
 n
g/
m
l (
E
L
IS
A
)
10
3
C
G
 +
 w
ee
kl
y 
T
Fi
rs
t l
in
e
18
%
 v
s.
 2
1%
6.
1 
vs
. 7
.0
12
.2
 v
s.
 N
R
K
ru
g 
et
 a
l.3
5
P
ha
se
 I
I,
 r
an
do
m
iz
ed
S
tr
at
ifi
ca
ti
on
 
ac
co
rd
in
g 
H
E
R
2 
IH
C
 s
ta
tu
s
64
w
ee
kl
y 
D
 +
 T
 v
s.
 w
ee
kl
y 
P
 +
 T
Fi
rs
t l
in
e
23
%
 v
s.
 3
2%
N
R
16
 v
s.
 1
4
L
ar
a 
et
 a
l.6
4
P
ha
se
 I
I,
 r
an
do
m
iz
ed
H
E
R
2 
IH
C
 2
+
/3
+
 
or
 H
E
R
2 
am
pl
ifi
ca
ti
on
13
In
du
ct
io
n 
w
it
h 
D
 o
r T
 w
ee
kl
y.
 A
ft
er
 
in
du
ct
io
n 
ph
as
e,
 a
ll
 p
at
ie
nt
s 
re
ce
iv
ed
 th
e 
co
m
bi
na
ti
on
 o
f 
w
ee
kl
y 
D
 +
 T
<
2 
pr
io
r 
no
na
nt
hr
ac
yc
li
ne
-
co
nt
ai
ni
ng
 
ch
em
ot
he
ra
py
8%
4.
3
5.
7
Z
in
ne
r 
et
 a
l.6
3
P
ha
se
 I
I,
 
no
nr
an
do
m
iz
ed
H
E
R
2 
IH
C
 1
+
/2
+
/3
+
 
or
 s
er
um
 H
E
R
2 
le
ve
ls
 >
15
 n
g/
m
l 
(E
L
IS
A
)
21
 (
pr
em
at
ur
el
y 
st
op
pe
d)
C
G
 +
 w
ee
kl
y 
T
Fi
rs
t l
in
e
38
%
T
T
P
 8
.5
 m
on
th
s
O
ne
-y
ea
r 
su
rv
iv
al
 r
at
e 
of
 6
2%
C
G
, 
ci
sp
la
ti
n–
ge
m
ci
ta
bi
ne
; 
C
P,
 c
ar
bo
pl
at
in
–p
ac
li
ta
xe
l;
 D
, 
D
oc
et
ax
el
; 
P,
 p
ac
li
ta
xe
l;
 T
, 
tr
as
tu
zu
m
ab
; 
N
S
C
L
C
s,
 n
on
–s
m
al
l-
ce
ll
 l
un
g 
ca
nc
er
; 
O
R
R
, 
ov
er
al
l 
re
sp
on
se
 r
at
e;
 P
R
, 
pa
rt
ia
l 
re
sp
on
se
; 
P
F
S
, 
pr
og
re
ss
io
n-
fr
ee
 s
ur
vi
va
l;
 O
S
, 
ov
er
al
l s
ur
vi
va
l;
 I
H
C
, i
m
m
un
oh
is
to
ch
em
is
tr
y;
 E
L
IS
A
, e
nz
ym
e-
li
nk
ed
 im
m
un
os
or
be
nt
 a
ss
ay
; T
T
P,
 ti
m
e 
to
 p
ro
gr
es
si
on
. C
R
, c
om
pl
et
e 
re
sp
on
se
; N
R
, n
ot
 r
ep
or
te
d,
 C
A
L
G
B
, C
an
ce
r 
an
d 
L
eu
ke
m
ia
 G
ro
up
 B
; E
C
O
G
, E
as
te
rn
 C
oo
pe
ra
tiv
e 
O
nc
ol
og
y 
G
ro
up
.
1756 Copyright © 2014 by the International Association for the Study of Lung Cancer
Rita et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 12, December 2014
TA
b
LE
 3
. 
Se
le
ct
ed
 S
tu
di
es
 R
ep
or
tin
g 
H
ER
2 
A
m
pl
ifi
ca
tio
n 
by
 F
IS
H
 in
 N
SC
LC
St
ud
y
Sa
m
pl
e 
Si
ze
 (
n
)
H
ys
to
ty
pe
H
E
R
2 
A
m
pl
ifi
ca
ti
on
 (
F
IS
H
)
C
ri
te
ri
a 
fo
r 
G
en
e 
A
m
pl
ifi
ca
ti
on
/F
IS
H
 P
os
it
iv
it
y
C
om
m
en
ts
C
ap
pu
zz
o 
et
 a
l.5
3
19
0
N
S
C
L
C
s
28
.8
%
P
ts
 w
er
e 
cl
as
si
fi
ed
 in
to
 tw
o 
st
ra
ta
: F
IS
H
 n
eg
at
iv
e,
 w
it
h 
no
 o
r 
lo
w
 g
en
om
ic
 g
ai
n 
(≤
4 
co
pi
es
 o
f 
th
e 
ge
ne
 in
 
>
40
%
 o
f 
ce
ll
s)
 a
nd
 F
IS
H
 p
os
it
iv
e,
 w
it
h 
a 
hi
gh
 le
ve
l 
of
 p
ol
ys
om
y 
(≥
4 
co
pi
es
 o
f 
th
e 
ge
ne
 in
 ≥
40
%
 o
f 
ce
ll
s)
 
or
 g
en
e 
am
pl
ifi
ca
ti
on
, d
efi
ne
d 
by
 p
re
se
nc
e 
of
 ti
gh
t 
ge
ne
 c
lu
st
er
s 
an
d 
a 
ra
ti
o 
of
 g
en
e/
ch
ro
m
os
om
e 
pe
r 
ce
ll
 
≥2
, o
r 
≥1
5 
co
pi
es
 o
f 
th
e 
ge
ne
s 
pe
r 
ce
ll
 in
 ≥
 1
0%
 o
f 
an
al
yz
ed
 c
el
ls
.
N
o 
pr
og
no
st
ic
 r
ol
e.
 N
o 
di
ff
er
en
ce
 in
 te
rm
s 
of
 r
es
po
ns
e 
to
 C
T
 b
et
w
ee
n 
F
IS
H
 p
os
it
iv
e 
an
d 
ne
ga
tiv
e 
pt
s;
 H
E
R
2 
F
IS
H
-
po
si
tiv
e 
pt
s 
tr
ea
te
d 
w
it
h 
an
 
E
G
F
R
 T
K
I 
ha
d 
hi
gh
er
 R
R
, 
T
T
P,
 a
nd
 O
S
. I
n 
H
E
R
2 
F
IS
H
-
ne
ga
tiv
e 
pt
s 
C
T
 p
ro
du
ce
d 
hi
gh
er
 R
R
 a
nd
 lo
ng
er
 T
T
P
 
th
an
 T
K
Is
.
C
ap
uz
zo
 e
t a
l.4
2
10
2
N
S
C
L
C
22
.8
%
P
ts
 w
er
e 
cl
as
si
fi
ed
 in
to
 tw
o 
st
ra
ta
: F
IS
H
 n
eg
at
iv
e,
 w
it
h 
no
 o
r 
lo
w
 g
en
om
ic
 g
ai
n 
(≤
4 
co
pi
es
 o
f 
th
e 
ge
ne
 in
 
>
40
%
 o
f 
ce
ll
s)
 a
nd
 F
IS
H
 p
os
it
iv
e,
 w
it
h 
a 
hi
gh
 le
ve
l 
of
 p
ol
ys
om
y 
(≥
4 
co
pi
es
 o
f 
th
e 
ge
ne
 in
 ≥
40
%
 o
f 
ce
ll
s)
 
or
 g
en
e 
am
pl
ifi
ca
ti
on
, d
efi
ne
d 
by
 p
re
se
nc
e 
of
 ti
gh
t 
ge
ne
 c
lu
st
er
s 
an
d 
a 
ra
ti
o 
of
 g
en
e/
ch
ro
m
os
om
e 
pe
r 
ce
ll
 
≥2
, o
r 
≥1
5 
co
pi
es
 o
f 
th
e 
ge
ne
s 
pe
r 
ce
ll
 in
 ≥
 1
0%
 o
f 
an
al
yz
ed
 c
el
ls
.
F
IS
H
-p
os
it
iv
e 
pt
s 
tr
ea
te
d 
w
it
h 
ge
fi
ti
ni
b 
ex
pe
ri
en
ce
d 
be
tt
er
 
O
R
R
, ,
 a
nd
 lo
ng
er
 T
T
P.
 T
he
 
ou
tc
om
e 
of
 d
ou
bl
e-
po
si
tiv
e 
pt
s 
w
as
 s
ig
ni
fi
ca
nt
ly
 b
et
te
r 
th
an
 th
at
 o
f 
th
e 
H
E
R
2 
F
IS
H
-
ne
ga
tiv
e/
E
G
F
R
-p
os
it
iv
e 
or
 
H
E
R
2-
ne
ga
tiv
e 
an
d/
or
 E
G
F
R
-
ne
ga
tiv
e 
pt
s.
C
ox
 e
t a
l.1
6
34
4
N
S
C
L
C
s
Fo
ur
 c
as
es
 (
al
l I
H
C
 3
+
)
H
E
R
2 
ge
ne
 a
m
pl
ifi
ca
ti
on
 w
as
 d
efi
ne
d 
as
 a
 H
E
R
2:
 
ch
ro
m
os
om
e 
17
 r
at
io
 >
2.
0
D
an
ie
le
 e
t a
l.4
3
42
N
S
C
L
C
0%
 a
m
pl
ifi
ca
ti
on
; 3
8%
 (
hi
gh
  
co
py
 n
um
be
r)
F
IS
H
 r
es
ul
ts
 f
or
 H
E
R
2 
ge
ne
s 
w
er
e 
as
se
ss
ed
 u
si
ng
 th
e 
fo
ll
ow
in
g 
ca
te
go
ri
es
: b
al
an
ce
d 
di
so
m
y 
(1
.6
–2
.0
  
ge
ne
s 
an
d 
ch
ro
m
os
om
es
 in
 a
ll
 c
el
ls
),
 b
al
an
ce
d 
 
tr
is
om
y 
(2
.2
–3
.0
 g
en
es
 a
nd
 c
hr
om
os
om
es
 in
 a
t l
ea
st
 
10
 c
el
ls
),
 b
al
an
ce
d 
po
ly
so
m
y 
(3
.1
–4
.4
 g
en
es
 a
nd
 
ch
ro
m
os
om
es
 in
 a
t l
ea
st
 1
0 
ce
ll
s)
, l
ow
 a
m
pl
ifi
ca
ti
on
 
(g
en
e/
ch
ro
m
os
om
es
 2
.1
–3
.0
),
 a
nd
 h
ig
h 
am
pl
ifi
ca
ti
on
 
(g
en
e/
ch
ro
m
os
om
es
 >
3)
.
O
nl
y 
co
nc
ur
re
nt
 g
ai
n 
of
 b
ot
h 
H
E
R
2 
an
d 
E
G
F
R
 g
en
es
 w
er
e 
as
so
ci
at
ed
 w
it
h 
ge
fi
ti
ni
b 
se
ns
it
iv
it
y
H
ei
nm
öl
le
r 
et
 a
l.2
0
56
3
N
S
C
L
C
s
1,
8%
 (
4%
 in
 A
D
C
s)
H
E
R
2 
ge
ne
 a
m
pl
ifi
ca
ti
on
 w
as
 d
efi
ne
d 
as
 a
 H
E
R
2:
 
ch
ro
m
os
om
e 
17
 r
at
io
 >
2.
0
H
ir
sc
h 
et
 a
l.2
1
Fi
ft
y-
on
e 
pt
s 
ev
al
ua
te
d
N
S
C
L
C
s
4%
 (
8%
 in
 A
D
C
s 
on
ly
)
H
E
R
2 
ge
ne
 a
m
pl
ifi
ca
ti
on
 w
as
 d
efi
ne
d 
as
 a
 H
E
R
2:
 
ch
ro
m
os
om
e 
17
 r
at
io
 >
2.
0
Ju
nk
er
 e
t a
l.4
0
(A
) 
10
5 
(p
re
tr
ea
tm
en
t)
;(
B
) 
44
 (
af
te
r 
ne
oa
dj
uv
an
t 
th
er
ap
y)
N
S
C
L
C
 (
II
IA
 N
2,
 I
II
B
)
(A
) 
4.
8%
; (
B
) 
4.
6%
. N
o 
tu
m
or
s 
w
it
h 
hi
gh
 g
ra
de
 a
m
pl
ifi
ca
ti
on
 
in
 b
ot
h 
gr
ou
ps
.
F
IS
H
 s
ig
na
ls
 o
f 
40
 n
on
ov
er
la
pp
in
g 
nu
cl
ei
 o
f 
tu
m
or
  
ce
ll
s 
w
er
e 
co
un
te
d 
an
d 
th
e 
m
ea
n 
va
lu
e 
w
as
  
ca
lc
ul
at
ed
; m
ea
n 
va
lu
es
 b
el
ow
 3
.5
 w
er
e 
re
ga
rd
ed
 
as
 p
hy
si
ol
og
ic
al
, t
ho
se
 o
f 
4.
5 
an
d 
hi
gh
er
 a
s 
‘‘
am
pl
ifi
ca
ti
on
.’’
T
re
nd
 to
w
ar
d 
a 
m
in
or
 r
es
po
ns
e 
to
 n
eo
ad
ju
va
nt
 th
er
ap
y.
 H
E
R
2 
ov
er
ex
pr
es
si
on
/a
m
pl
ifi
ca
ti
on
 
w
as
 s
li
gh
tly
 h
ig
he
r 
in
 A
D
C
s;
 
no
 c
or
re
la
ti
on
 w
it
h 
st
ag
e
L
ar
a 
et
 a
l.6
4
69
N
S
C
L
C
 (
II
IB
/I
V
)
Tw
o 
of
 1
4 
pt
s 
(r
at
io
>
2)
H
E
R
2/
C
E
P
17
 r
at
io
 p
er
 c
el
l ≥
1.
0
M
ee
rt
 e
t a
l.2
7
12
9
N
S
C
L
C
s
6%
 (
5%
 in
 S
qC
C
 a
nd
 1
%
 in
 
A
D
C
s)
H
E
R
2/
C
E
P
17
 r
at
io
 p
er
 c
el
l >
2
H
E
R
2 
am
pl
ifi
ca
ti
on
 a
ss
oc
ia
te
d 
w
it
h 
sh
or
te
r 
su
rv
iv
al
Pe
ll
eg
ri
ni
 e
t a
l.1
08
41
N
S
C
L
C
s
22
%
; 7
%
 h
ig
h-
le
ve
l g
en
e 
am
pl
ifi
ca
ti
on
A
m
pl
ifi
ca
ti
on
 w
as
 c
la
ss
ifi
ed
 a
s 
lo
w
-l
ev
el
 a
m
pl
ifi
ca
ti
on
 
(3
–5
 H
E
R
-2
 s
po
ts
 p
er
 c
hr
om
os
om
e 
17
 c
en
tr
om
er
e)
 
an
d 
hi
gh
-l
ev
el
 a
m
pl
ifi
ca
ti
on
 (
>
5 
H
E
R
-2
 s
po
ts
 p
er
 
ch
ro
m
os
om
e 
17
 c
en
tr
om
er
e)
Pe
lo
si
 e
t a
l.2
3
34
5
N
S
C
L
C
s 
(S
ta
ge
 I
)
7.
4%
H
E
R
2 
ge
ne
 a
m
pl
ifi
ca
ti
on
 w
as
 d
efi
ne
d 
as
 a
 H
E
R
2:
 
ch
ro
m
os
om
e 
17
 r
at
io
 >
2.
0
N
o 
re
la
ti
on
sh
ip
 w
it
h 
su
rv
iv
al
(C
on
ti
nu
ed
)
1757Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 12, December 2014 NSCLC and HER2
S
oh
 e
t a
l.6
7
74
N
S
C
L
C
43
.2
%
 (
hi
gh
 c
op
y 
nu
m
be
r)
C
la
ss
ifi
ca
ti
on
 o
f 
pt
s 
in
to
 s
ix
 s
tr
at
a 
ac
co
rd
in
g 
to
 c
ri
te
ri
a 
pr
op
os
ed
 b
y 
C
ap
pu
zz
o 
et
 a
l.4
2
H
ig
h 
H
E
R
2 
co
py
 n
um
be
r 
w
as
 
si
gn
ifi
ca
nt
ly
 a
ss
oc
ia
te
d 
w
it
h 
se
ns
it
iv
it
y 
to
 g
efi
ti
ni
b 
an
d 
pr
ol
on
ge
d 
P
F
S
 in
 a
 
un
iv
ar
ia
te
 a
na
ly
si
s,
 b
ut
 n
ot
 in
 
a 
m
ul
tiv
ar
ia
te
 a
na
ly
si
s.
Ta
ke
za
w
a 
et
 a
l.7
5
99
A
D
C
1%
H
E
R
2/
C
E
P
17
 r
at
io
 p
er
 c
el
l >
2 
or
 h
om
og
en
eo
us
ly
 
st
ai
ni
ng
 r
eg
io
ns
 w
it
h 
>
15
 c
op
ie
s 
in
 >
10
%
 o
f 
th
e 
ce
ll
s 
pr
es
en
t
Ta
n 
et
 a
l.2
2
14
0
N
S
C
L
C
s 
(S
ta
ge
 I
–I
II
A
)
5%
H
E
R
2 
ge
ne
 a
m
pl
ifi
ca
ti
on
 w
as
 d
efi
ne
d 
as
 a
 H
E
R
2:
 
ch
ro
m
os
om
e 
17
 r
at
io
 >
2.
0
P
ts
 w
it
h 
H
E
R
-2
 a
m
pl
ifi
ca
ti
on
 
ex
hi
bi
te
d 
a 
sh
or
te
r 
su
rv
iv
al
.
T
is
eo
 e
t a
l.6
8
58
N
S
C
L
C
19
%
C
la
ss
ifi
ca
ti
on
 o
f 
pt
s 
in
to
 s
ix
 s
tr
at
a 
ac
co
rd
in
g 
to
 c
ri
te
ri
a 
pr
op
os
ed
 b
y 
C
ap
pu
zz
o 
et
 a
l.4
2
N
o 
si
gn
ifi
ca
nt
 d
if
fe
re
nc
es
 in
 
te
rm
s 
of
 r
es
po
ns
e 
or
 s
ur
vi
va
l 
in
 p
at
ie
nt
s 
tr
ea
te
d 
w
it
h 
ge
fi
ti
ni
b.
 C
on
cu
rr
en
t E
G
F
R
 
an
d 
H
E
R
2 
F
IS
H
 p
os
it
iv
it
y 
di
d 
no
t c
or
re
la
te
 w
it
h 
re
sp
on
se
 to
 
ge
fi
ti
ni
b.
V
ar
el
la
-G
ar
ci
a 
et
 a
l.7
1
44
N
S
C
L
C
53
%
Pa
ti
en
ts
 w
er
e 
gr
ou
pe
d 
in
to
 tw
o 
st
ra
ta
: (
1)
 F
IS
H
 n
eg
at
iv
e 
in
cl
ud
in
g 
di
so
m
y 
to
 lo
w
 p
ol
ys
om
y 
tu
m
or
s,
 w
hi
ch
 
ba
si
ca
lly
 h
av
e 
fo
ur
 c
op
ie
s 
of
 th
e 
ge
ne
 in
 <
40
%
 o
f 
ce
ll
s;
 a
nd
 (
2)
 F
IS
H
 p
os
it
iv
e 
in
cl
ud
in
g 
tu
m
or
s 
w
it
h 
hi
gh
 p
ol
ys
om
y 
(≥
4 
co
pi
es
 in
 ≥
40
%
 o
f 
ce
ll
s)
 a
nd
 g
en
e 
am
pl
ifi
ca
ti
on
 (
de
fi
ne
d 
by
 a
 r
at
io
 g
en
e/
ch
ro
m
os
om
e 
pe
r 
ce
ll
 ≥
2,
 p
re
se
nc
e 
of
 s
m
al
l o
r 
no
ne
nu
m
er
ab
le
 c
lu
st
er
s 
of
 th
e 
ge
ne
 s
ig
na
l o
r 
≥1
5 
co
pi
es
 o
f 
th
e 
ge
ne
 s
ig
na
l i
n 
≥1
0%
 o
f 
th
e 
an
al
yz
ed
 c
el
ls
).
N
o 
di
ff
er
en
ce
 in
 te
rm
s 
of
 T
T
P
 
an
d 
O
S
 f
or
 p
ts
 tr
ea
te
d 
w
it
h 
ge
fi
ti
ni
b
C
E
P,
 c
hr
om
os
om
e 
en
um
er
at
io
n 
pr
ob
es
; N
S
C
L
C
s,
 n
on
–s
m
al
l-
ce
ll
 lu
ng
 c
an
ce
r;
 C
T,
 c
om
pu
te
d 
to
m
og
ra
ph
y;
 R
R
, r
es
po
ns
e 
ra
te
; T
T
P,
 ti
m
e 
to
 p
ro
gr
es
si
on
; O
S
, o
ve
ra
ll
 s
ur
vi
va
l;
 O
R
R
, o
ve
ra
ll
 r
es
po
ns
e 
ra
te
; D
C
R
, d
is
ea
se
 c
on
tr
ol
 r
at
e;
 
A
D
C
, a
de
no
ca
rc
in
om
as
; P
F
S
, p
ro
gr
es
si
on
-f
re
e 
su
rv
iv
al
; S
qC
C
, s
qu
am
ou
s 
ce
ll
 c
ar
ci
no
m
a;
 F
IS
H
, fl
uo
re
sc
en
ce
 in
 s
it
u 
hy
br
id
iz
at
io
n;
 p
ts
, p
at
ie
nt
s.
St
ud
y
Sa
m
pl
e 
Si
ze
 (
n
)
H
ys
to
ty
pe
H
E
R
2 
A
m
pl
ifi
ca
ti
on
 (
F
IS
H
)
C
ri
te
ri
a 
fo
r 
G
en
e 
A
m
pl
ifi
ca
ti
on
/F
IS
H
 P
os
it
iv
it
y
C
om
m
en
ts
TA
b
LE
 3
. 
(C
on
tin
ue
d)
1758 Copyright © 2014 by the International Association for the Study of Lung Cancer
Rita et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 12, December 2014
mechanism of acquired resistance that occurs in 49–62% of 
cases76,77 explaining, at least in part, why the dual blockage 
with afatinib–cetuximab induces response in some but not 
all patients without T790M-mediated acquired resistance.75 
Pretreatment specimens were not available for HER2 FISH 
analysis in these three HER2-amplified tumors to exclude the 
presence of this genetic dysregulation before TKIs exposure. 
However, they conducted HER2 FISH on 99 untreated adeno-
carcinomas, demonstrating HER2 amplification in only one 
tumor (1%).
These results were confirmed by Yu et al.77 in a large 
series of 155 patients with EGFR-mutant NSCLC who under-
went rebiopsy after acquiring resistance to EGFR TKIs. 
Interestingly, they reported in 4% of patients the overlap of 
different mechanisms of resistance, including one patient 
with the concurrent presence of T790M and HER2 amplifica-
tion, suggesting that distinct mechanisms of resistance may 
exist in separate clones of the tumor, further underlying the 
heterogeneous nature of acquired resistance. Unfortunately, 
they were unable to perform HER2 FISH assay in pretreat-
ment specimens and in all rebiopsy specimens (only 24 of 155 
were analyzed for HER2 amplification), making difficult to 
draw definitive conclusions about the real prevalence of these 
acquired genetic aberrations and the true prevalence of over-
lap mechanisms.
The activity of anti-HER2 agents in HER2 amplified 
tumors has been only marginally analyzed in the phase II trials 
evaluating trastuzumab in NSCLC, due to the low frequency of 
this genetic abnormality. However, in the study of Gatzemeier 
et al.62 investigating the addition of trastuzumab to cisplatin–
gemcitabine, the small fraction of patients exhibiting strong 
HER2 expression and/or amplification showed higher RR and 
longer progression-free survival (PFS) compared with low-
expressing/FISH-negative patients, suggesting a possible ben-
efit in this highly selected patient population. The discovery 
of HER2 amplification as a mechanism of acquired resistance 
to the EGFR TKIs has renewed the interest on trastuzumab in 
NSCLC and a phase II trial, evaluating the trastuzumab–pacli-
taxel combination in patients with EGFR activating mutation, 
progressed on EGFR TKIs and with HER2 IHC positive stain-
ing at rebiopsy, is ongoing (NCT02226757).
Lapatinib, the dual EGFR/HER2 inhibitor, was evalu-
ated in a phase II study in an unselected NSCLC population, 
with a minimal single agent activity; however, patients with 
HER2 amplification may derive some benefit from lapatinib 
activity because one of the two patients with HER2 amplifica-
tion had a 51% decrease in tumor measurement.77
HER2 MUTATIONS AND THE REDISCOVERY OF 
HER2 PATHWAY IN NSCLC
In 2004, Stephens et al.79 first reported the presence of 
somatic mutations in the tyrosine kinase domain of HER2 in 
NSCLC. Sequencing the HER2 gene from 120 NSCLC sam-
ples, they detected in 4.2% of cases four in-frame mutations 
and one missense substitution, located in the kinase domain of 
HER2, that were analog of the in-frame deletions of the EGFR. 
Moreover, these genetic alterations were mutually exclusive 
with other known oncogenic drivers (EGFR, KRAS2, NRAS, 
and BRAF), seemed not to be associated with HER2 IHC 
staining or HER2 amplification and to be more frequent in 
adenocarcinomas (9.8%) and in current or former smokers (4 
of 5 patients), but some cases carrying other oncogenic drivers 
have been reported subsequently.80
In vitro studies demonstrated that exon 20 mutations 
of the HER2 cause constitutive activation in a ligand-inde-
pendent fashion of the receptor. From these studies emerged 
that they signal more potently than the wild-type counterpart 
and are markedly more transformant than HER2wT. Moreover, 
they are essential for tumor maintenance, insensitive to EGFR 
TKIs action, but still sensitive to HER2-targeted therapies.81–84
From the initial report of Stephens et al.,79 other groups 
have progressively demonstrated the presence of HER2 muta-
tions in several human malignancies, including breast85,86 and 
colorectal cancer87 and urothelial carcinoma.88 From these 
studies, it has emerged that the type and location of HER2 
mutations in nonlung tumors are different from those observed 
in NSCLC, with a higher prevalence of missense mutations 
over deletions/insertions and the involvement of exons other 
than 20, suggesting that functional mechanisms of the HER2 
mutations in other tumor types might be different from that of 
lung cancer.87
The presence of HER2 mutations defines a molecu-
lar subset of NSCLC with specific clinic-pathological fea-
tures: Asian ethnicity,89 female sex,80,90,91 never smoking 
status,89,90,92,93 and adenocarcinoma histology89,92 even with 
bronchiolalveolar feaures,94 high morphologic grade,93 TTF-1 
positive staining,90 peculiar clinical presentations (dissemi-
nated lung nodules and tumor excavation),80 but seems to have 
similar survival compared with other molecularly defined 
cohorts.93 Despite the more prevalence in specific subgroups 
of patients, HER2 mutations may be found in men and heavy 
smokers, suggesting that HER2 testing could be guided more 
properly by histology rather than other clinical characteris-
tics.80,93 Recently, Barlesi et al.94 in a large biomarker study 
in 10,000 advanced NSCLC white patients reported a HER2 
mutational frequency of 0.9%.
The presence of HER2 mutations has been correlated 
in some case series with HER2 and EGFR copy number gain 
(CNG). Indeed, in the study of Li et al.91 among eight sam-
ples harboring HER2 mutations, seven showed HER2 CNG 
(four amplification and three high polysomy) and five showed 
EGFR CNG. However, larger case series did not find any asso-
ciation between HER2 mutations and gene amplification, sug-
gesting that HER2 gain cannot serve as a surrogate marker.80,93
Recently, Yamamoto et al. described a novel HER2 
mutation (G660D) in a Japanese family with multiple cases 
of lung cancer. Using a whole-exome sequencing, they first 
identified a germline mutation in the transmembrane domain 
of HER2 and then, assuming that HER2 transmembrane 
domain mutations might act as driver mutations, sequenced 
exon 17 of the HER2 gene in 315 NSCLC samples (253 were 
adenocarcinomas), identifying an additional transmembrane 
mutation (V659E) in one patient with a nonmucinous adeno-
carcinoma in situ. The V659E mutation is the human analog 
of the V664E in rat that was previously described to induce 
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oncogenic transformation. Indeed, they were able to report 
preliminary data supporting its role as oncogenic driver in 
NSCLC.96
p95HER2, also known as HER2 carboxyl terminal 
fragment, is a truncated isoform of HER2 receptor that lacks 
substantial parts of the extracellular domain and has been 
predominantly found in breast cancers, causing resistance to 
trastuzumab.97 To evaluate the clinical impact of this altera-
tion in NSCLC, Cappuzzo et al.98 reported that p95HER2 is 
present in less than 10% of NSCLC patients, mainly in the 
absence of HER2 amplification or mutation and has no prog-
nostic effect.
Preclinical studies reveled that HER2-mutant tumors 
are relatively insensitive to EGFR TKIs,81–83 albeit at differ-
ent extent, probably due to differences in HER2 expression 
levels.99 These data were confirmed in the clinical setting 
because patients with NSCLC harboring HER2 mutations do 
not respond to gefitinib100,101 or show only modest activity.90
The discovery of HER2 mutations and the preclinical 
evidence of activity of anti-HER2 agents, along with the unre-
sponsiveness to other molecular agents, prompted the clini-
cal testing of HER2-blocking agent in patients harboring this 
genetic aberration.
In 2006, Cappuzzo et al. first reported in vivo activity of 
the anti-HER2 monoclonal antibody trastuzumab in a 60-year-
old female nonsmoker with metastatic adenocarcinoma of the 
lung that had not responded to conventional chemotherapy 
and EGFR TKI gefitinib. Treatment with weekly trastuzumab 
and paclitaxel resulted in a partial response. The analysis 
of the tissue specimen revealed the presence of an exon 20 
HER2 mutation.8 Encouraged by this preliminary report, other 
authors have reported promising results in HER2-mutant 
patients treated with weekly trastuzumab and vinorelbine.90
More recently, Falchook et al.102 reported an impressive 
and durable response to dual HER2 inhibition with trastu-
zumab and lapatinib in combination with the antiangiogenic 
agent bevacizumab in a heavily pretreated patient with an 
exon 20 insertion of HER2, enrolled into a phase I trial.
Preclinical data have shown that irreversible pan-ERBB 
inhibitor neratinib (HKI-272) inhibits most of the HER2 
mutants at similar extent than EGFR L858R mutant cells.82,99 
Recently, Gandhi et al.103 reported intriguing results of a phase 
I study with the dual combination neratinib and the mTOR 
inhibitor temsirolimus. Activity was noted in HER2-driven 
cancers, suggesting a dependence on Akt/mTOR pathways 
for NSCLC with HER2 exon 20 mutations. Two of the seven 
patients with HER2-mutant NSCLC in this study remained 
on treatment for more than 6 months (1 PR and 1 SD) despite 
multiple prior therapies (including one with prior trastu-
zumab) and encouraging activity was seen even in two of three 
patients with NSCLC harboring EGFR-resistant mutations.103 
A phase II study evaluating this combination is ongoing in 
HER2-amplified breast cancer and HER2-mutant NSCLC 
(NCT01827267).
Perera et al.83 first reported preclinical efficacy of the 
pan-HER inhibitor afatinib in HER2-mutant NSCLC, with 
an intriguing activity for the combination with the mTOR 
inhibitor rapamycin. De Grève et al.104 reported evidence of in 
vivo activity of afatinib in patients harboring exon 20 HER2 
mutations who had been previously treated with various che-
motherapy regimens and anti-EGFR and/or HER2 agents, 
enrolled in an open-label phase II trial with afatinib.
Dacomitinib, another irreversible pan-HER inhibitor, 
has shown in vitro activity in NSCLC cell lines harboring 
EGFR and HER2 mutations as well as HER2-amplified.105 
Kelly et al.106 reported a case of an EGFR and HER2 wild-
type NSCLC patient with co-expression of EGFR and HER2 
that responded to dacomitinib (PR) and, after progression, was 
treated with trastuzumab and vinorelbine, with benefit. The 
preliminary results of the HER2-mutant or amplified cohort 
of a phase II study with dacomitinib in advanced NSCLC 
have been reported.107 In HER2-mutant NSCLC, an overall 
13% RR (all with HER2 exon 20 insertions, with no responses 
observed in the two patients with HER2 point mutations) was 
reported with a PFS of 3 months and a preliminary estimated 
OS of 10 months. In contrast, no responses were reported in 
the HER2-amplified cohort and the PFS ranged from 1 to 5 
months.107
Recently, Mazières et al. analyzing the largest cohort 
of HER2-mutated NSCLC (n = 65) reported so far, showed 
encouraging clinical data with various anti-HER2 agents. 
Among the 22 patients evaluable, they reported an overall 
response rate of 50% with a DCR of 82% and a PFS of 5.1 
months with various anti-HER2 agents. In particular, they 
observed a DCR of 96% for trastuzumab-containing chemo-
therapy regimens and 100% for afatinib monotherapy, with 
no response for lapatinib and masatinib as single agents.80 
However, the retrospective nature of this study, the limited 
fraction of patients treated with anti-HER2 agents and the het-
erogeneity of treatments does not allow definitive conclusions 
about the prognostic and predictive value of HER2 mutations 
in NSCLC and deserves prospective evaluation in molecularly 
selected clinical trials.
The availability of multiple biomarkers platforms, 
as demonstrated by NSCLC Biomarker French National 
Program94 and the Lung Cancer Mutational Consortium,7 
may help identification and treatment of patients with these 
rare abnormalities. Recently, the National Cancer Institute 
launched a series of clinical studies with the overall aim being 
to use more precise diagnostics to allow selection of patients 
for targeted therapies. Of particular interest, the National 
Cancer Institute MATCH study will target molecule abnor-
malities directed by next generation sequencing and will 
“MATCH” patients with appropriate targeted agents, acting as 
an umbrella protocol with multiple molecular-based phase II 
studies.109 There is an urgent need of innovative clinical study 
design in NSCLC and initiative like the MATCH trial may 
help a broader use of molecularly targeted agents even in rare 
clinical subsets.
CONCLUSIONS AND FUTURE PERSPECTIVES
The picture of HER2 pathway that emerges from the 
studies conducted so far is rather complex. However, the dis-
covery of HER2 mutations and the clinical demonstration of 
activity of anti-HER2 agents in this particular molecular set-
ting have renewed interest on the role of HER2 pathway in 
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NSCLC, bringing back the attention on anti-HER2 therapies 
in NSCLC and providing novel possible indications for irre-
versible pan-HER inhibitors that are currently tested in other 
molecularly defined subgroups.
Moreover, the association of HER2 amplification with 
acquired resistance to first-generation EGFR TKIs deserves 
further investigations and may provide the rationale for tar-
geting HER2 pathway in this clinical setting. with these 
premises, a bright future seems to expect HER2 pathway 
in NSCLC with the hope that as soon as possible could be 
numbered among the other shining examples of oncogene-
addicted tumors, getting closer the era of personalized 
medicine.
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